Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced today that the first patient has been enrolled in the HORIZON Phase 2 trial evaluating TNX-102 SL 5.6 mg as a first-line monotherapy for adults with major depressive disorder (MDD). The randomized, double-blind, placebo-controlled study is expected to enroll approximately 360 patients at about 30 U.S. sites and will assess changes in depression severity after six weeks of treatment, along with measures of sleep quality, anxiety and global clinical improvement.
TNX-102 SL is designed to improve sleep quality, which the company believes plays an important role in MDD, and is already approved by the FDA under the brand name TONMYA™ for the treatment of fibromyalgia in adults. Tonix said the therapy has previously shown signals for improving depressive symptoms and subjective sleep quality in earlier clinical studies and is also being developed for several additional indications, including post-traumatic stress disorder, Long COVID, alcohol use disorder and agitation in Alzheimer’s disease.
The news matters because MDD affects millions of people worldwide, and current treatments often have limited efficacy or significant side effects. If TNX-102 SL proves effective as a first-line monotherapy, it could offer a new option for patients who do not respond well to existing antidepressants. Additionally, since TNX-102 SL is already approved for fibromyalgia, its safety profile is better understood, potentially accelerating regulatory pathways.
For leaders in business and technology, the implications extend beyond healthcare. Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments. The company’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® SymTouch® and Tosymra®. Tonix is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder.
In addition, the company’s CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
Investors and industry observers should watch for interim data from the HORIZON trial, as positive results could significantly expand Tonix’s addressable market and validate the therapeutic approach of targeting sleep quality in MDD. The latest news and updates relating to TNXP are available in the company’s newsroom at https://nnw.fm/TNXP.
For more information on Tonix Pharmaceuticals, visit the company’s website or view the full press release at https://nnw.fm/dORql.
Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.
